ArticleEJNMMI research2019
Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease.
Article in EJNMMI research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Clinical applications of PET imaging for evaluating treatment-induced vascular toxicity in oncology.Current opinion in hematology · 2026Review
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- PET Imaging of CD38 and IND enabling studies of [Molecular imaging and biology · 2026Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Emerging PET radiotracers for vascular imaging.Rheumatology (Oxford, England) · 2025Review
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET.Frontiers in endocrinology · 2023Review
- Predictive markers for anti-inflammatory treatment response in thyroid eye disease.Frontiers in endocrinology · 2023Review
- Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.Journal of ophthalmic inflammation and infection · 2021Review
- Ultrasound and Bioptic Investigation of Patients with Primary Sjögren's Syndrome.Journal of clinical medicine · 2021Review
- Imaging in Primary Sjögren's Syndrome.Journal of clinical medicine · 2020Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Zirconium-89 labelled rituximab PET-CT imaging of Graves' orbitopathy.European journal of nuclear medicine and molecular imaging · 2020Article
- New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.Mediators of inflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrbital inflammatory diseases are a heterogenic group of conditions that often entail a difficult diagnostic process and many patients are treatment resistant. Inflammatory diseases can be visualized by Zirconium-89-labelled rituximab PET-CT (
resultsRetrospectively,
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.